Abstract
Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1710-1716 |
| Number of pages | 7 |
| Journal | Journal of Vascular Surgery |
| Volume | 57 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2013 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Surgery
Cite this
Current medical and surgical management of Raynaud's syndrome. / Landry, Gregory.
In: Journal of Vascular Surgery, Vol. 57, No. 6, 06.2013, p. 1710-1716.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current medical and surgical management of Raynaud's syndrome
AU - Landry, Gregory
PY - 2013/6
Y1 - 2013/6
N2 - Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.
AB - Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.
UR - http://www.scopus.com/inward/record.url?scp=84880836467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880836467&partnerID=8YFLogxK
U2 - 10.1016/j.jvs.2013.03.012
DO - 10.1016/j.jvs.2013.03.012
M3 - Article
C2 - 23618525
AN - SCOPUS:84880836467
VL - 57
SP - 1710
EP - 1716
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
SN - 0741-5214
IS - 6
ER -